Value £2,350,000

Newcells Biotech

VC Funding

Series A

Healthcare & Biotech Published 14 February 2024

Summary

In a significant market movement during February 2024, Newcells Biotech was the subject of a vc funding. The transaction achieved a gross valuation of £2,350,000. Leading the round was North East Venture Fund, Mercia Ventures, European regional development fund (ERDF), Northstar Ventures.

This transaction was brokered by an undisclosed advisor. The deal reflects ongoing market confidence within its sector.

Lead Investor / Acquirer

North East Venture Fund

Lead Investor / Acquirer

Mercia Ventures

Lead Investor / Acquirer

European regional development fund (ERDF)

Lead Investor / Acquirer

Northstar Ventures

Advising Broker

Undisclosed Firm

Related Deals in Healthcare & Biotech

Series A prioritised

VC Funding

Luna Pet Healthcare

£700,000

May 2026

VC Funding

Koalaa

£941,985

Feb 2024

VC Funding

TalkLife

Undisclosed

Feb 2024

VC Funding

Healthily

£23,225,064

Oct 2020

View Company Details

Financials, officers, full deal history

Original Source

This funding round is sourced from the Tech.eu Funding Explorer. View the full record, investors, and citations there.

View on Tech.eu Funding Explorer

Funding data via Tech.eu Funding Explorer, licensed under CC BY 4.0. See our methodology.

AI Insight Lenses

Pro

AI-generated analysis from four professional perspectives. Powered by PE Deals.

Free to all registered users.